Vascular Unit, Aberdeen Royal Infirmary, United Kingdom.
Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.
Omega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease. We aimed to determine if Omega-3 fatty acid supplementation in addition to best medical therapy can reduce the increased platelet and endothelial activity that is present in patients with intermittent claudication.
One hundred and fifty patients who were receiving aspirin and statin therapy were recruited into a randomised cross-over double blind study involving 6 week supplementation with OMACOR fish oil (850-882 mg eicosapentaenoic and docosahexaenoic acid) versus placebo. A 12 week washout period occurred between treatments. Patients with diabetes were excluded. For each outcome a random effects model was fitted in which treatment and period were fixed effects and patients were random effects.
Omega-3 supplementation had no effect on the primary outcome measure von Willebrand factor. Similarly Omega-3 supplementation resulted in no change in unstimulated or stimulated P-selectin expression and fibrinogen binding, or platelet aggregation (Ultegra point of care). Pulse wave velocity was also unchanged. High-sensitivity C-reactive protein, s-ICAM and IL-6 were also unchanged.
Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.
ω-3 脂肪酸已被证明可减少心脏病患者或有心脏病风险患者的血小板和内皮细胞激活。我们旨在确定在最佳药物治疗的基础上补充 ω-3 脂肪酸是否可以降低间歇性跛行患者中存在的血小板和内皮细胞活性增加。
招募了 150 名正在接受阿司匹林和他汀类药物治疗的患者，他们参与了一项随机交叉双盲研究，涉及 6 周补充 OMACOR 鱼油（850-882mg 二十碳五烯酸和二十二碳六烯酸）与安慰剂。两种治疗之间有 12 周的洗脱期。排除患有糖尿病的患者。对于每个结果，都拟合了一个随机效应模型，其中治疗和周期是固定效应，患者是随机效应。
ω-3 补充对主要测量指标 von Willebrand 因子没有影响。同样，ω-3 补充对未刺激或刺激的 P-选择素表达和纤维蛋白原结合，或血小板聚集（Ultegra 即时护理）没有影响。脉搏波速度也没有变化。高敏 C 反应蛋白、s-ICAM 和 IL-6 也没有变化。
补充 ω-3 脂肪酸对周围动脉疾病患者的血小板和内皮细胞激活或炎症标志物没有影响。
